Published in Cancer on June 01, 2000
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol (2010) 2.04
Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ (2001) 1.19
Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br J Cancer (2004) 1.11
The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg (2012) 1.04
Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer. World J Surg (2002) 0.91
Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer (2002) 0.89
The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis (2012) 0.87
Clinical efficacy and problems with CT lymphography in identifying the sentinel node in breast cancer. World J Surg Oncol (2008) 0.85
Fluorescent radiocolloids: are hybrid tracers the future for lymphatic mapping? Eur J Nucl Med Mol Imaging (2015) 0.76
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science (1990) 3.70
Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. J Immunol (1988) 3.65
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg (1999) 3.56
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Feasibility and effects of decision aids. Med Decis Making (2000) 2.83
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Biological properties of interleukin 10. J Clin Immunol (1992) 2.50
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31
No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol (2001) 2.31
How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer (1991) 2.10
[Guideline 'Melanoma' (3rd revision)]. Ned Tijdschr Geneeskd (2005) 2.08
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat (1998) 1.97
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Campylobacter jejuni non-culturable coccoid cells. Int J Food Microbiol (1992) 1.89
Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol (1992) 1.87
Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol Rev (1988) 1.84
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg (2001) 1.79
Assessing the privacy risks of data sharing in genomics. Public Health Genomics (2010) 1.78
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol (2008) 1.69
Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J (1999) 1.62
Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS (2001) 1.59
HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet (1999) 1.59
Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol (1999) 1.55
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol (2002) 1.54
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Aneurysmal bone cysts treated by curettage, cryotherapy and bone grafting. J Bone Joint Surg Br (1997) 1.53
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol (2005) 1.52
Measurement by nerve fiber analyzer of retinal nerve fiber layer thickness in normal subjects and patients with ocular hypertension. Am J Ophthalmol (1996) 1.52
Concordance of phenprocoumon dosage in married couples. BMJ (1997) 1.51
Malignant struma ovarii treated by ovariectomy, thyroidectomy, and 131I administration. Cancer (1987) 1.50
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst (1988) 1.50
Lymph node metastasis from melanoma with an unknown primary site. Br J Surg (1990) 1.49
Quality of life and health status before and after ileal pouch-anal anastomosis for ulcerative colitis. Br J Surg (2011) 1.49
Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol (2001) 1.49
Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a systematic review of quantitative studies. Psychooncology (2012) 1.48
Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (1998) 1.47
High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg (2004) 1.46
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol (2002) 1.46
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol (2001) 1.44
Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg (2007) 1.43
[Diagnostics in clinically occult, radiologically suspect breast lesions more often surgery than needle diagnostics with image monitoring]. Ned Tijdschr Geneeskd (2001) 1.43
Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas (2010) 1.43
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet (2000) 1.42
Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res (2000) 1.42
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
Evaluation of quality of life in sarcoidosis patients. Respir Med (1998) 1.40
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2004) 1.40
Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making (1998) 1.39
Finding lymph node metastases in invasive breast cancer: sampling or sentinel node procedure? Eur J Surg Oncol (2002) 1.39
Quantitative assessment of calf circumference in Duchenne muscular dystrophy patients. Neuromuscul Disord (2002) 1.38
[Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma]. Ned Tijdschr Geneeskd (1993) 1.38
Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene (2007) 1.37
Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life. J Clin Oncol (2001) 1.36
Isolation and characterization of an expressible cDNA encoding human IL-3. Induction of IL-3 mRNA in human T cell clones. J Immunol (1988) 1.36
Self-expanding and balloon-expandable stents in the treatment of carotid aneurysms: an experimental study in a canine model. AJNR Am J Neuroradiol (1994) 1.36
[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35
Percutaneous vertebroplasty and pulmonary cement embolism: results from VERTOS II. AJNR Am J Neuroradiol (2010) 1.33
Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology (2001) 1.32